Breaking News, Collaborations & Alliances

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Septerna Inc. and Novo Nordisk have entered an exclusive global collaboration and license agreement to discover, develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programs for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors. Marcus Schindler, EVP and CSO of N...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters